logo

KREBSBIO vs SYNCOMF: Stock Comparison

KREBS BIOCHEMICALS & IND vs SYNCOM FORMU (I)Updated 22 Oct 26, 4:08 PM ISTNSE & company filings

SYNCOM FORMU (I) is the larger company by market capitalisation. KREBS BIOCHEMICALS & IND shows a lower P/E and faster revenue growth, while SYNCOM FORMU (I) shows a higher dividend yield, a higher ROCE and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

KREBSBIO leads 3; SYNCOMF leads 6 of 11

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

KREBSBIOSYNCOMF

Valuation lens

What price are you paying?

Market CapContext only
₹125 Cr
₹2,053 Cr
P/E RatioKREBSBIO has the lower reading
0x ✓
24x
P/B RatioKREBSBIO has the lower reading
0x ✓
4.95x
EPSSYNCOMF has the higher reading
₹-1.15
₹0.26 ✓
Book ValueContext only
—
₹4.41
Dividend YieldSYNCOMF has the higher reading
0%
0.45% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SYNCOMF is the larger company
₹2,053 Cr vs ₹125 Cr
P/E Ratio
KREBSBIO has a lower P/E
0x vs 24x
P/B Ratio
KREBSBIO has a lower P/B
0x vs 4.95x
EPS
SYNCOMF has higher earnings per share
₹0.26 vs ₹-1.15
Dividend Yield
SYNCOMF has a higher dividend yield
0.45% vs 0%
Revenue Growth (TTM YoY)
KREBSBIO has faster revenue growth
11.6% vs -9%
EPS Growth (TTM YoY)
SYNCOMF has faster EPS growth
68.8% vs 0%
ROCE
SYNCOMF has a higher ROCE
18.57% vs -15.89%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKREBSBIOSYNCOMF
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKREBSBIOSYNCOMF
Live Price₹57.48₹22.08
Day Change2.53%0.05%
Volume3,5702.26 Cr
52-Week High₹76.85₹27.49
52-Week Low₹38.33₹10.21
Distance from 52W High-25.2%-19.68%

Valuation

MetricKREBSBIOSYNCOMF
Market Cap₹125 Cr₹2,053 Cr
P/E Ratio0x24x
P/B Ratio0x4.95x
EPS₹-1.15₹0.26
Book Value—₹4.41
Dividend Yield0%0.45%

Growth

MetricKREBSBIOSYNCOMF
Revenue Growth (TTM YoY)11.6%-9%
EPS Growth (TTM YoY)0%68.8%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricKREBSBIOSYNCOMF
ROE—18.42%
ROCE-15.89%18.57%
Net Margin-71.35%15.63%
Operating Margin-41.49%20.91%
Debt to Equity—0x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricKREBSBIOSYNCOMF
Promoter Holding72.74%50.57%
FII Holding0.5%2.22%▲ 1.87 pp
DII Holding0%0%
Public Holding26.76%47.2%▼ 1.88 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KREBS BIOCHEMICALS & IND and SYNCOM FORMU (I).

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.